# Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

> **NCT02141074** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 54 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia B

## Interventions

- **DRUG:** nonacog beta pegol

## Key facts

- **NCT ID:** NCT02141074
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-02
- **Primary completion:** 2022-10-27
- **Final completion:** 2022-10-27
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02141074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02141074, "Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02141074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*